Ultralife's 15min chart shows KDJ Death Cross, bearish Marubozu formation detected.
PorAinvest
miércoles, 13 de agosto de 2025, 3:16 pm ET2 min de lectura
ULBI--
The revenue increase was driven primarily by the inclusion of Electrochem, which offset flat organic sales in the Battery & Energy Products segment. However, the Communications Systems segment saw a significant drop in sales, declining by 57.2% to $2.7 million, due to delayed purchase orders and prior year shipments. This segment's gross profit also fell, contributing to the overall decline in profitability [2].
Tariffs and unfavorable product mix further impacted Ultralife's gross margin, leading to a 100 basis point reduction in profitability. The company expects the Communications Systems business to rebound in the second half of 2025, with early purchase orders from new battery product programs and increased demand from medical and oil & gas sectors. Additionally, Ultralife anticipates sustained growth in global defense spending [1].
Ultralife's net income for the quarter was $900,000, down from $2.7 million in the same period last year. The company also reported operating expenses of $9.3 million, with a one-time adjustment of $300,000 for the Mississauga closure. The company's debt reduction efforts continued, with $2.7 million of acquisition debt repaid [2].
The company's adjusted EBITDA was $4.1 million, down from $5.4 million in the previous quarter. The trailing twelve months adjusted EBITDA was $15.4 million. Ultralife's working capital was $69.1 million, with a current ratio of 3.3, and no draws made under the $30 million revolver. The company also received the full employee retention credit of $1.8 million, which was applied to debt [2].
Ultralife's CEO, Mike Manna, highlighted the company's ongoing supply chain challenges and margin improvement efforts focused on pricing, cost controls, and vertical integration stemming from the Electrochem acquisition. The company is also pursuing multiple new product launches and qualification activities, including new server cases, amplifiers, and thin cell batteries. However, management expressed caution on quantifying near-term revenue impact as sales pipelines are still converting from evaluation to orders [2].
Ultralife initiated litigation targeting recovery in the millions of dollars for cyberattack-related insurance claims, which if successful could materially impact future results. The company cautions investors not to place undue reliance on forward-looking statements, reflecting current expectations. The potential risks and uncertainties that could cause actual results to differ materially include uncertain global economic conditions, reductions in revenues from key customers, delays or reductions in U.S. and foreign military spending, acceptance of new products on a global basis, and disruptions or delays in the supply of raw materials and components [2].
Ultralife shares had fallen by 9.1% this quarter and gained 9.5% so far this year [1]. The 15-minute chart for Ultralife has triggered a KDJ Death Cross and a Bearish Marubozu at 08/13/2025 15:00, indicating a shift in the momentum of the stock price towards a downward trajectory, with a potential for further decline. Sellers are currently dominating the market, and there is a likelihood that the bearish momentum will continue [3].
References:
[1] Reuters. (2025). Ultralife Q2 revenue misses estimates. Retrieved from https://www.tradingview.com/news/reuters.com,2025:newsml_PLX442F4F:0-ultralife-q2-revenue-misses-estimates/
[2] MITrade. (2025). Ultralife Q2 Earnings Call Transcript. Retrieved from https://www.mitrade.com/insights/news/live-news/article-8-1021696-20250808
[3] Barchart. (2025). Ultralife Corporation reports second quarter results. Retrieved from https://www.barchart.com/story/news/33956140/ultralife-corporation-reports-second-quarter-results
The 15-minute chart for Ultralife has triggered a KDJ Death Cross and a Bearish Marubozu at 08/13/2025 15:00. This indicates a shift in the momentum of the stock price towards a downward trajectory, with a potential for further decline. Sellers are currently dominating the market, and there is a likelihood that the bearish momentum will continue.
Ultralife Corporation (ULBI) reported mixed financial results for the second quarter of 2025, with revenues up 13% year-over-year to $48.6 million, but missing analyst expectations. The company's gross profit was $11.6 million, or 23.9% of revenue, while operating income stood at $2.3 million, including one-time costs. GAAP EPS was $0.05, and adjusted EBITDA was $4.1 million [2].The revenue increase was driven primarily by the inclusion of Electrochem, which offset flat organic sales in the Battery & Energy Products segment. However, the Communications Systems segment saw a significant drop in sales, declining by 57.2% to $2.7 million, due to delayed purchase orders and prior year shipments. This segment's gross profit also fell, contributing to the overall decline in profitability [2].
Tariffs and unfavorable product mix further impacted Ultralife's gross margin, leading to a 100 basis point reduction in profitability. The company expects the Communications Systems business to rebound in the second half of 2025, with early purchase orders from new battery product programs and increased demand from medical and oil & gas sectors. Additionally, Ultralife anticipates sustained growth in global defense spending [1].
Ultralife's net income for the quarter was $900,000, down from $2.7 million in the same period last year. The company also reported operating expenses of $9.3 million, with a one-time adjustment of $300,000 for the Mississauga closure. The company's debt reduction efforts continued, with $2.7 million of acquisition debt repaid [2].
The company's adjusted EBITDA was $4.1 million, down from $5.4 million in the previous quarter. The trailing twelve months adjusted EBITDA was $15.4 million. Ultralife's working capital was $69.1 million, with a current ratio of 3.3, and no draws made under the $30 million revolver. The company also received the full employee retention credit of $1.8 million, which was applied to debt [2].
Ultralife's CEO, Mike Manna, highlighted the company's ongoing supply chain challenges and margin improvement efforts focused on pricing, cost controls, and vertical integration stemming from the Electrochem acquisition. The company is also pursuing multiple new product launches and qualification activities, including new server cases, amplifiers, and thin cell batteries. However, management expressed caution on quantifying near-term revenue impact as sales pipelines are still converting from evaluation to orders [2].
Ultralife initiated litigation targeting recovery in the millions of dollars for cyberattack-related insurance claims, which if successful could materially impact future results. The company cautions investors not to place undue reliance on forward-looking statements, reflecting current expectations. The potential risks and uncertainties that could cause actual results to differ materially include uncertain global economic conditions, reductions in revenues from key customers, delays or reductions in U.S. and foreign military spending, acceptance of new products on a global basis, and disruptions or delays in the supply of raw materials and components [2].
Ultralife shares had fallen by 9.1% this quarter and gained 9.5% so far this year [1]. The 15-minute chart for Ultralife has triggered a KDJ Death Cross and a Bearish Marubozu at 08/13/2025 15:00, indicating a shift in the momentum of the stock price towards a downward trajectory, with a potential for further decline. Sellers are currently dominating the market, and there is a likelihood that the bearish momentum will continue [3].
References:
[1] Reuters. (2025). Ultralife Q2 revenue misses estimates. Retrieved from https://www.tradingview.com/news/reuters.com,2025:newsml_PLX442F4F:0-ultralife-q2-revenue-misses-estimates/
[2] MITrade. (2025). Ultralife Q2 Earnings Call Transcript. Retrieved from https://www.mitrade.com/insights/news/live-news/article-8-1021696-20250808
[3] Barchart. (2025). Ultralife Corporation reports second quarter results. Retrieved from https://www.barchart.com/story/news/33956140/ultralife-corporation-reports-second-quarter-results
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios